FDA approves Avastin in glioblastoma

FDA granted accelerated approval of Avastin bevacizumab from Genentech Inc. for use in patients with previously treated glioblastoma multiforme (GBM). In March, an FDA advisory committee recommended accelerated approval based on Phase II data showing a quality of life benefit despite concerns regarding the reliability of objective response rate as measured using MRI (See BioCentury, April 06, 2009). ...